AGENUS INC (AGEN) 2.61 +0.06 (+2.35%)
2.61 +0.06 (+2.35%)
US00847G7051 - Common Stock - After market: 2.67 +0.06 (+2.3%)
Agenus to Participate in February Investor Conferences
Agenus to Participate in February Investor Conferences
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting...
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated patients; data suggest superior...
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics...
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
7 Hot Stocks to Book Profits In Before 2023
With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in.
Why Shares of Agenus Rose 12.5% on Friday
Agenus presented data this week on a combination therapy.
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of...
Noteworthy Wednesday Option Activity: AGEN, PETS, PLCE
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and...
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
AGEN stock spikes on Phase 1 data for cancer candidates (NASDAQ:AGEN)
Immuno-oncology company Agenus Inc. (AGEN) added ~11% on Monday after announcing data from a Phase 1 study for cancer candidates botensilimab and balstilimab in patients with...
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
Overall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung cancer...
Agenus (AGEN) Q3 2022 Earnings Call Transcript
AGEN earnings call for the period ending September 30, 2022.
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
Company to present expanded data from Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) at plenary session of the Society for Immunotherapy of Cancer...
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
Conference Call on Tuesday, November 8, 2022, at 8:30 a.m. ETCompany to host “The Road Taken” R&D Event in Boston on November 12 from 2p.m. – 5p.m. ET...
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with consistent high...